IMMUNIC IMUX 深 沪
等待开盘 11-01 09:30:00 美东时间
0.7788
-0.005
-0.69%
华盛通- 最 高0.7999
- 今 开0.79
- 成交量 87.08万股
- 最 低 0.775
- 昨 收 0.7842
- 总市值 7462.27万
- 52周最高 1.42
- 市盈率 静 --
- 换手率 0.91%
- 52周最低 0.561
- 委 比 -52.38%
- 总股本 9581.75万
- 历史最高 28.99
- 量 比 0.67
- 振 幅 3.18%
- 历史最低 0.561
- 每 手 1
- 风险率 0.15%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多ImmuCell Announces Preliminary, Unaudited Sales Results for Q3 of 2025
ImmuCell Corporation reported preliminary Q3 2025 sales of $5.5 million, down 8% from Q3 2024. The decline aligns with earlier guidance about reduced demand due to distributor inventory restocking following 2024 backlogs. Total trailing twelve-month sales reached $27.8 million, a 16% increase over the prior year. The company remains focused on rebuilding market share and developing its Re-Tain® product line for sustainable growth. A conference ca...
10-07 20:05
美股大行评级 | 潜在涨幅207.38%！GoldMining获HC Wainwright升目标价至3.75美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持GoldMining"买入"评级，目标价从3.25美元升至3.75美元；摩根士丹利：维持Crinetics Pharmaceuticals"超配"评级，目标价从65美元升至77美元
09-30 14:16
美股大行评级 | 潜在涨幅485.44%！Allarity Therapeutics获机构升目标价至9.25美元，维持"买入"评级
今日重点评级关注：Ascendiant Capital：维持Allarity Therapeutics"买入"评级，目标价从9美元升至9.25美元；JMP证券：维持Crinetics Pharmaceuticals"跑赢大市"评级，目标价从86美元升至143美元
09-29 09:15
美股大行评级 | 星展银行上调百度评级至"买入"，目标价177美元；多家机构上调Guardant Health(GH)目标价最高至80美元
今日重点评级关注：Ascendiant Capital：维持Aytu BioPharma"买入"评级，目标价从12美元升至12.5美元；Oppenheimer：维持Immuneering"跑赢大市"评级，目标价从21美元升至30美元
09-26 09:45
D. Boral Capital Maintains Buy on Immunic, Maintains $10 Price Target
D. Boral Capital analyst Jason Kolbert maintains Immunic (NASDAQ: IMUX) with a Buy and maintains $10 price target.
09-25 20:04
Immunic Presents Promising Phase 2 Trial Results
The latest announcement is out from Immunic ( ($IMUX) ). On September 25, 2025,...
09-25 19:28
Immunic Showcases Vidofludimus Calcium's MS Potential In Oral And Poster Presentations, Including Late-Breaker, At ECTRIMS 2025
– Vidofludimus Calcium Demonstrated Statistically Significant 24-Week Confirmed Disability Improvement in Phase 2 CALLIPER Trial in Progressive Multiple Sclerosis, With Over Two-Fold Probability Over Placebo in the
09-25 18:33
Immunic Secures New US Patent Protection for Multiple Sclerosis Drug Vidofludimus Calcium Through 2041
Immunic, Inc. (NASDAQ:IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced that
09-09 18:32
Analysts’ Top Healthcare Picks: Immunic (IMUX), Edgewise Therapeutics (EWTX)
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts jus...
08-12 18:20
D. Boral Capital Maintains Buy on Immunic, Maintains $10 Price Target
D. Boral Capital analyst Jason Kolbert maintains Immunic (NASDAQ:IMUX) with a Buy and maintains $10 price target.
08-08 20:33
